← All compounds

Ipamorelin

Human RCT Peptideshormonal recovery Last reviewed 2026-09-24

Summary

Ipamorelin is a selective growth hormone secretagogue (a ghrelin-receptor agonist) characterized in 1998 preclinical work for releasing GH with minimal cortisol or prolactin elevation. Human data are thin: early pharmacology studies plus one phase 2 trial for postoperative ileus that did not meet its primary endpoint.

Mechanism

Ipamorelin is a five-amino-acid peptide that acts as an agonist at the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus. Receptor activation triggers a pulse of growth hormone release from somatotrophs. Its distinguishing feature in preclinical work is selectivity: it provokes strong GH release with minimal elevation of cortisol, prolactin, or ACTH, unlike older growth hormone-releasing peptides such as GHRP-6.

Reported effects

Ratings are relative to peers in the same category, not absolute claims.

GH pulse amplitude★★★★☆Potent GH release demonstrated in preclinical models and early human pharmacology work.
IGF-1 elevation★★☆☆☆Follows from GH stimulation; magnitude in humans characterized only in small studies.
Body composition / recovery★☆☆☆☆No human trials support these uses; all claims rest on extrapolation.

Studied dosing: research context

Published human work used intravenous administration in early pharmacology studies and a phase 2 trial in bowel-resection patients. No published trial has studied subcutaneous dosing regimens for body-composition or performance outcomes in humans. This describes research protocols, not guidance.

Research context only. This is not a recommendation.

Safety

Human safety data are limited to early pharmacology studies and one phase 2 trial, in which the compound was generally tolerated with no major safety signal reported. There are no long-term safety studies, and no published data on repeated or chronic use in healthy adults. The selectivity profile was established with pharmaceutical-grade material; products of unknown provenance may differ.

Limitations

The only completed human RCT tested ipamorelin for postoperative bowel recovery, not body composition, performance, or aging. It missed its primary endpoint. There are no published trials testing the outcomes the compound is commonly discussed for. Preclinical selectivity findings may not translate to gray-market products of unknown identity and purity.

References

  1. Raun K et al., Eur J Endocrinol (1998): Ipamorelin, the first selective growth hormone secretagogue
  2. Beck DE et al., Int J Colorectal Dis (2014): Prospective, randomized, controlled, proof-of-concept study of ipamorelin for postoperative ileus in bowel resection patients